N/A
Manufactured by CVS WOONSOCKET PRESCRIPTION CENTER, INCORPORATED
1,126 FDA adverse event reports analyzed
Last updated: 2026-04-15
MOMETASONE FUROATE MONOHYDRATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by CVS WOONSOCKET PRESCRIPTION CENTER, INCORPORATED. The most commonly reported adverse reactions for MOMETASONE FUROATE MONOHYDRATE include DEATH, NAUSEA, DRUG INEFFECTIVE, DIARRHOEA, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for MOMETASONE FUROATE MONOHYDRATE.
Out of 501 classified reports for MOMETASONE FUROATE MONOHYDRATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 1,126 FDA FAERS reports that mention MOMETASONE FUROATE MONOHYDRATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DEATH, NAUSEA, DRUG INEFFECTIVE, DIARRHOEA, FATIGUE, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list CVS WOONSOCKET PRESCRIPTION CENTER, INCORPORATED in connection with MOMETASONE FUROATE MONOHYDRATE. Always verify the specific product and NDC with your pharmacist.